EV0 Stock Overview A specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Evoke Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Evoke Pharma Historical stock prices Current Share Price US$3.97 52 Week High US$15.00 52 Week Low US$0.33 Beta 0.38 1 Month Change 0% 3 Month Change -2.71% 1 Year Change -70.46% 3 Year Change -97.46% 5 Year Change -96.68% Change since IPO -99.69%
Recent News & Updates
Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024 Nov 09
Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director Oct 22 Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million. Aug 30
Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023) Aug 15
Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024 Aug 15
Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024 Aug 14 See more updates
Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024 Nov 09
Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director Oct 22 Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million. Aug 30
Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023) Aug 15
Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024 Aug 15
Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024 Aug 14
Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement Aug 02
First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.67 loss in 1Q 2023) May 16
Evoke Pharma, Inc., Annual General Meeting, May 22, 2024 Apr 11 Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024 Evoke Pharma, Inc. Provides Earnings Guidance for 2024 Mar 15
New major risk - Revenue and earnings growth Mar 15
Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024 Mar 08
Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2) Feb 26
New major risk - Shareholder dilution Feb 10 Evoke Pharma, Inc. has completed a Follow-on Equity Offering. Feb 09
Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq Nov 29
Evoke Pharma Receives Notice from Nasdaq Nov 23 Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million. Nov 11
Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.60 loss in 3Q 2022) Nov 11
New major risk - Revenue and earnings growth Nov 10 Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million. Nov 10
Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI Nov 03
Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI Sep 15
Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022) Aug 11
Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance Jul 23
Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market May 29
First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.80 loss in 1Q 2022) May 18
Full year 2022 earnings released: US$2.62 loss per share (vs US$3.18 loss in FY 2021) Mar 23
Evoke Pharma, Inc. Announces Executive Changes Feb 14
Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti Jan 31
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023 Jan 19
Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.73 loss in 3Q 2021) Nov 11
Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 03
Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray Sep 21
Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.85 loss in 2Q 2021) Aug 12
Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 04
Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use Jul 07
Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program Jun 16
Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update Jun 09
Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported May 24
Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI® May 19
No longer forecast to breakeven May 12
Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
Evoke Pharma Granted FDA Market Exclusivity for Gimoti® Apr 27
Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List Apr 20
Insufficient new directors Mar 17
No longer forecast to breakeven Mar 09
Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Mar 03
Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI Feb 18
Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray Jun 16
Evoke Pharma, Inc. Announces the Launch of Wave 1 of an Innovative Social Media Campaign to Reach Patients Directly with Education About Diabetic Gastroparesis May 28
Independent Director has left the company May 19
No longer forecast to breakeven May 19
Revenue misses expectations Mar 13
Evoke Pharma, Inc. to Report Q4, 2020 Results on Mar 11, 2021 Mar 05
New 90-day low: €2.00 Jan 30
Evoke Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million. Jan 15
Evoke Pharma, Inc. Announces, Through its Marketing Partner, Eversana Life Science Services, LLC, Conducted an ATU (Awareness, Trial, and Usage) Study, Quantitative Survey to Measure Physician Awareness, Trial, and Product Usage, for GIMOTI Jan 14
New 90-day low: €2.07 Dec 29
Co-Founder recently sold €173k worth of stock Dec 16
New 90-day low: €2.37 Dec 12
New 90-day low: €2.70 Nov 19
New 90-day low: €3.26 Nov 04
Evoke Pharma, Inc. and Eversana Life Science Services, LLC Announce Commercial Launch of Gimoti™ Oct 29
New 90-day high - €3.60 Aug 10 Shareholder Returns EV0 DE Pharmaceuticals DE Market 7D 0% -0.2% -0.4% 1Y -70.5% -17.1% 7.9%
See full shareholder returns
Return vs Market: EV0 underperformed the German Market which returned 19.6% over the past year.
Price Volatility Is EV0's price volatile compared to industry and market? EV0 volatility EV0 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.1% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: EV0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine EV0's volatility change over the past year.
About the Company Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Show more Evoke Pharma, Inc. Fundamentals Summary How do Evoke Pharma's earnings and revenue compare to its market cap? EV0 fundamental statistics Market cap €5.36m Earnings (TTM ) -€6.04m Revenue (TTM ) €6.96m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EV0 income statement (TTM ) Revenue US$7.53m Cost of Revenue US$227.94k Gross Profit US$7.30m Other Expenses US$13.83m Earnings -US$6.53m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -7.97 Gross Margin 96.97% Net Profit Margin -86.75% Debt/Equity Ratio 187.6%
How did EV0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/10/29 07:56 End of Day Share Price 2024/08/01 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Evoke Pharma, Inc. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju Aegis Capital Corporation Edward Woo Ascendiant Capital Markets LLC Difei Yang Brean Capital
Show 9 more analysts 
